Potential for immunotherapy in the treatment of herpesvirus infections

Herpes

Volumn 8, Issue 1, 2001, Pages 8-11

  Bernstein, D I ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Genital herpes; Herpes simplex virus; Herpes zoster virus; Imiquimod; Immune response modifiers; Immunotherapy; Ocular herpes; Recurrent genital herpes; Vaccines

Indexed keywords

IMIQUIMOD; MURAMYL PEPTIDE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; RESIQUIMOD; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; VIRUS GLYCOPROTEIN;

CLINICAL TRIAL; EYE INFECTION; GENITAL HERPES; GUINEA PIG; HERPES; HERPES SIMPLEX VIRUS 1; HERPES ZOSTER; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION CONTROL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW;

ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; GUINEA PIGS; HERPES GENITALIS; HERPES ZOSTER; HERPESVIRIDAE INFECTIONS; HERPESVIRUS VACCINES; HUMANS; IMMUNOTHERAPY, ACTIVE; RECURRENCE;

ANIMALIA; CAVIA PORCELLUS; HERPES; HERPES ZOSTER; HERPES ZOSTER VIRUS; HERPESVIRIDAE; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS; SUS SCROFA;

EID: 0035070845     PISSN: 09697667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Formalized herpes virus therapy and the neutralization substances in herpes simplex
2. Herpes simplex virus glycoprotein treatment of recurrent genital herpes
3. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes
4. Evaluation of herpes simplex virus vaccines in animals: The guinea pig vaginal model
5. Detection and characterization of latent HSV RNA by in situ and northern blot hybridization in guinea pigs
6. Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes; factors influencing efficacy
7. Herpes simplex virus glycoprotein treatment of recurrent genital herpes reduces cervicovaginal virus shedding in guinea pigs
8. Antigen-presenting liposomes are effective in treatment of recurrent herpes simplex virus genitalis in guinea pigs
9. Liposome-formulated interleukin-2 as an adjuvant of recombinant HSV glycoprotein gD for the treatment of recurrent genital HSV-2 in guinea-pigs
10. Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use
11. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine
12. Immunotherapy of acute and recurrent herpes simplex virus type 2 infection with an adjuvant-free form of recombinant glycoprotein D-interleukin-2 fusion protein
13. Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea-pigs
14. Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent, and latent genital infections with herpes simplex virus type 2 in guinea pigs
15. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease
16. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1
17. Efficacy of a recombinant glycoprotein D subunit vaccine on the development of primary and recurrent ocular infection with herpes simplex virus type 1 in mice
18. A therapeutic vaccine that reduces recurrent herpes simplex virus type 1 corneal disease
19. Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits
20. Cell-mediated immunologic responses and recurrent genital herpes in the guinea pig. Effects of glycoprotein immunotherapy
21. Th1/Th2-like immunity and resistance to herpes simplex labialis
22. Gamma interferon production appears to predict time of recurrence of herpes labialis
23. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: Results of a placebo-controlled vaccine trial
24. Herpes simplex virus vaccine in recurrent herpetic ocular infection
25. Possible role of varicella vaccine in preventing herpes zoster
26. Herpes zoster in the elderly: Issues related to geriatrics
27. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: Duration of booster effect
28. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: A randomized, controlled, dose-response trial
29. Imiquimod applied topically: A novel immune response modifier and new class of drug
30. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod
31. Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463
32. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection
33. Post-therapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs
34. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine
35. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs
36. Daily or weekly therapy with resiquimod reduces genital recurrences in herpes simplex virus infected guinea pigs during and after treatment
37. Immunomodulation to decrease recurrences of herpes genitalis: A double-blind, dose ranging study of topical R-848